NYSE Content Advisory: Pre-Market Update + President of South Korea rings Opening Bell
NEW YORK, Sept. 25, 2025 /PRNewswire/ -- The New York Stock Exchange…
Bybit Brings Back Daily Treasure Hunt With October’s “Hot Token Rush”
DUBAI, UAE, Sept. 26, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange…
NYSE Content Advisory: Pre-Market Update + Wall Street digests August PCE data
NEW YORK, Sept. 26, 2025 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market update + Health partners with NBA’s Charlotte Hornets + Proofpoint unveils Satori
NEW YORK, Sept. 24, 2025 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market update + Mike Waltz, U.S. Ambassador to UN, rings Opening Bell
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The New York Stock Exchange…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
China Daily: CAEXPO highlights AI innovations to foster cross-border tech fair
BEIJING, Sept. 19, 2025 /PRNewswire/ -- The 22nd China-ASEAN Expo, held from Wednesday…
NYSE Content Advisory: Pre-Market Update + Russell 2000 hits first record since 2021
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + Fed cuts interest rates by 0.25%
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The New York Stock Exchange…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…